EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Edward V. Loftus  ¹     Jean-Frédéric Colombel  ²     Ana Paula Lacerda  ³     Laurent Peyrin-Biroulet  ⁴     Geert R. D'Haens  ⁵     Remo Panaccione  ⁶     Walter Reinisch     Edouard Louis     Minhu Chen     Hiroshi Nakase     Susan Greenbloom     Aaron Duvall     Yuri Sanchez Gonzalez     Mohamed-Eslam F. Mohamed     Susan Rhee     Tian Feng     Elena Dubcenco     Julian Panés    
¹ Mayo Clinic College of Medicine and Science, Rochester, United States
² Icahn School of Medicine at Mount Sinai, New York City, United States
³ AbbVie, North Chicago, United States
⁴ University Hospital of Nancy, Lorraine University, Vandoeuvre, France
⁵ Amsterdam University Medical Centers, Amsterdam, Netherlands
⁶ University of Calgary,

Session
Clinical trials in Crohn's disease

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)